The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain

Bibliography

• Baron R, Binder A, Wasner G. Neuropathic pain. Diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9:807-19
   PubMed Web of Science ®Google Scholar
• Hoitsma E. Small fiber neuropathy: a novel finding in sarcoidosis. PhD thesis, University of Maastricht; 2005
   Google Scholar
• Tavee J, Culver S. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep 2011;15:201-6
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O'Connor AB, Audette J, Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:S3-14
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Otto M, McQuay HJ, Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305
   PubMed Web of Science ®Google Scholar
• Brines M, Patel NS, Villa P, Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008;105:10925-30
   PubMed Web of Science ®Google Scholar
• Ahmet I, Tae HJ, Juhaszova M, A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage. Mol Med 2011;17:194-200
   Google Scholar
• Polgarova K, Luthje P, Cerami A, Brauner A. The erythropoietin analogue ARA 290 modulates the innate response and reduces Escherichia coli invasion into urothelial cells. FEMS Immunol Med Microbiol 2011;62:190-6
   Google Scholar
• Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. New Engl J Med 2007;357:2153-65
   PubMed Web of Science ®Google Scholar
• Costabel U. Sarcoidosis: clinical update. Eur Respir J 2001;18(Suppl 32):56s-68s
   Google Scholar
• Izbicki G, Chavko R, Banauch GI, World Trade Center “sarcoid-like” granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest 2007;131:1414-23
   PubMed Web of Science ®Google Scholar
• Hoitsma E, Marziniak M, Faber CG, Small fibre neuropathy in sarcoidosis. Lancet 2002;359(9323):2085-6
   PubMed Web of Science ®Google Scholar
• Hoitsma E, De Vries J, Drent M. The small fiber neuropathy screening list: construction and cross-validation in sarcoidosis. Respir Med 2011;105:95-100
   PubMed Web of Science ®Google Scholar
• Hoitsma E, Faber CG, van Kroonenburgh MJ, Association of small fiber neuropathy with cardiac sympathetic dysfunction in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:43-50
   Google Scholar
• Hoitsma E, Reulen JP, De BM, Small fiber neuropathy: a common and important clinical disorder. J Neurol Sci 2004;227:119-30
   PubMed Web of Science ®Google Scholar
• Burns TM, Dyck PJB, Aksamit AJ, Dyck PJ. The natural history and long-term outcome of 57 limb sracoidosis neuropathy cases. J Neurol Sci 2006;244:77-87
   PubMed Web of Science ®Google Scholar
• Baughmann RP, Iannuzzi M. Tumour necrosis factor in sarcoidosis ands its potential for targeted therapy. BioDrugs 2003;17:425-31
   Google Scholar
• Baughmann RP, Drent M, Kavuru M, Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795-802
   Google Scholar
• Hoitsma E, Faber CG, van Santen-Hoeufft M, Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006;23:73-7
   PubMed Web of Science ®Google Scholar
• Cerami A. TNF and EPO: major players in the innate immune response: their discovery. Ann Rheum Dis 2012;71(Supp II):i55-9
   Google Scholar
• Brines M, Cerami A. The receptor that tames the innate immune response. Mol Med 2012;18:486-96
   PubMed Web of Science ®Google Scholar
• Brines M, Grasso G, Fiordaliso F, Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101:14907-12
   PubMed Web of Science ®Google Scholar
• Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Int Med 2008;262:405-32
   Google Scholar
• Brines ML, Ghezzi P, Keenan S, Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10536-1
   Google Scholar
• Grasso G, Graziano F, Sfacteria A, Neuroprotective effect of erythropoietin and darbepoietin alfa after experimental intracerebral hemorrhage. Neurosurg 2009;65:763-9
   PubMed Web of Science ®Google Scholar
• Liao ZB, Zhi XG, Shi QH, He ZH. Recombinant human erythropoietin administration protects cortical neurons from traumatic brain injury in rats. Eur J Neurol 2008;15:140-9
   PubMed Web of Science ®Google Scholar
• Corwin HL, Gettinger A, Fabian TC, Efficacy and safety of epoietin alfa in critically ill patients. N Engl J Med 2007;357:965-76
   PubMed Web of Science ®Google Scholar
• Leist M, Ghezzi P, Grasso G, Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-42
   PubMed Web of Science ®Google Scholar
• Erbayraktar Z, Erbayraktar S, Yilmaz O, Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing. Mol Med 2009;15:235-41
   PubMed Web of Science ®Google Scholar
• Swartjes M, Morariu A, Niesters M, ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and beta-common receptor knockout mice. Anesthesiology 2011;115:1084-92
   PubMed Web of Science ®Google Scholar
• Bianchi R, Buyukakilli B, Brines M, Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA 2004;101:823-8
   PubMed Web of Science ®Google Scholar
• Campana WM, Li X, Shubayev VI, Erythropoietin reduces schwann cell TNF-alpha, Wallerian degeneration and pain-related behaviors after peripheral nerve injury. Eur J Neurosci 2006;23:617-26
   PubMed Web of Science ®Google Scholar
• Suter MR, Papaloizos M, Berde CB, Development of neuropathis pain in the rat spared nerve injury model is not prevented by a peripheral nerve block. Anesthesiology 2003;99:1402-8
   PubMed Web of Science ®Google Scholar
• Tanga FY, Raghavendra V, DeLeo JA. Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain. Neurochem Int 2004;45:397-407
   PubMed Web of Science ®Google Scholar
• Empl M, Renaud S, Erne B, TNF-alpha expression in painful and nonpainful neuropathies. Neurology 2001;56:1371-7
   PubMed Web of Science ®Google Scholar
• Homma Y, Brull SJ, Zhang JM. A comparison of chronic pain behavior following local application of tumor necrosis factor [alpha] to the normal and mechanically compressed lumbar ganglia in the rat. Pain 2002;95:239-46
   PubMed Web of Science ®Google Scholar
• Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 2004;45:89-95
   PubMed Web of Science ®Google Scholar
• Zhang L, Berta T, Xu ZZ, TNF-alpha contributes to spinal cord synaptic plasticity and inflammatory pain: distinct role of TNF receptor subtypes 1 and 2. Pain 2011;152:419-27
   PubMedGoogle Scholar
• Jia H, Feng X, Li W, Recombinant human erythropoietin attenuates spinal neuroimmune activation of neuropathic pain in rats. Ann Clin Lab Sci 2009;39:84-91
   PubMed Web of Science ®Google Scholar
• Jia H, Jin Y, Ji Q, Effects of recombinant erythropoietin on neuropathic pain and cerebral expressions of cytokines and nuclear factor-kappa B. Can J Anesth 2009;56:597-603
   Google Scholar
• Dahan A, Olofsen E, Sigtermans M, Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain. Eur J Pain 2011;15:258-67
   PubMed Web of Science ®Google Scholar
• Dahan A, Heij L, Niesters M, Safety and efficacy of ARA 290 in neuropathy associated with sarcoidosis: a pilot study. In preparation
   Google Scholar
• Burgess G, Williams D. The discovery and development of analgesics: new mechanisms, new modalities. J Clin Invest 2010;120:3753-9
   PubMed Web of Science ®Google Scholar
• Kuner R. Central mechanisms of pathological pain. Nat Med 2010;16:1258-66
   PubMed Web of Science ®Google Scholar
• Woolf CJ. What is this thing called pain? J Clin Invest 2010;120:3742-4
   PubMed Web of Science ®Google Scholar
• Noppers I, Niesters M, Aarts L, Ketamine for treatment of chronic non-cancer pain. Expert Opin Pharmacother 2010;11:2417-29
   PubMed Web of Science ®Google Scholar
• Sigtermans M, van Hilten JJ, Bauer MCR, Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain 2009;145:304-11
   PubMed Web of Science ®Google Scholar